Poised to become law, the BIOSECURE Act will have ramifications for certain US-China pharmaceutical relationships.

Depo Provera’s label change comes amidst a flurry of over 2,000 lawsuits from women alleging that the contraceptive caused ...

The EC has approved Incyte’s Minjuvi (tafasitamab) with lenalidomide and rituximab for adults with relapsed or refractory FL.

Alnylam Pharmaceuticals is to invest $250m to expand its facility in Massachusetts, US, to meet the growing demand for RNAi ...